Brokerages expect Acorda Therapeutics, Inc. (NASDAQ:ACOR) to report sales of $177.37 million for the current quarter, according to Zacks Investment Research. Eight analysts have provided estimates for Acorda Therapeutics’ earnings. The highest sales estimate is $219.93 million and the lowest is $144.92 million. Acorda Therapeutics posted sales of $140.63 million during the same quarter last year, which suggests a positive year over year growth rate of 26.1%. The company is scheduled to report its next quarterly earnings results on Tuesday, February 13th.

On average, analysts expect that Acorda Therapeutics will report full-year sales of $177.37 million for the current fiscal year, with estimates ranging from $544.81 million to $619.81 million. For the next fiscal year, analysts anticipate that the firm will post sales of $404.24 million per share, with estimates ranging from $310.96 million to $488.45 million. Zacks Investment Research’s sales averages are a mean average based on a survey of sell-side research analysts that follow Acorda Therapeutics.

Acorda Therapeutics (NASDAQ:ACOR) last released its quarterly earnings data on Tuesday, October 31st. The biopharmaceutical company reported $0.43 EPS for the quarter, missing the Thomson Reuters’ consensus estimate of $0.69 by ($0.26). Acorda Therapeutics had a negative return on equity of 8.18% and a negative net margin of 10.25%. The business had revenue of $141.07 million during the quarter, compared to the consensus estimate of $150.64 million. During the same period last year, the business posted ($0.04) earnings per share. The firm’s quarterly revenue was up 4.0% on a year-over-year basis.

Several equities analysts recently commented on the stock. Janney Montgomery Scott reaffirmed a “hold” rating and set a $18.00 target price on shares of Acorda Therapeutics in a report on Wednesday, August 30th. ValuEngine raised shares of Acorda Therapeutics from a “sell” rating to a “hold” rating in a report on Monday, October 2nd. Piper Jaffray Companies reaffirmed a “neutral” rating and set a $22.00 target price on shares of Acorda Therapeutics in a research note on Tuesday, November 28th. J P Morgan Chase & Co set a $24.00 target price on shares of Acorda Therapeutics and gave the company a “hold” rating in a research note on Tuesday, October 31st. Finally, Cantor Fitzgerald reaffirmed a “hold” rating and set a $18.00 target price on shares of Acorda Therapeutics in a research note on Tuesday, October 31st. Four equities research analysts have rated the stock with a sell rating, eleven have issued a hold rating, two have assigned a buy rating and one has given a strong buy rating to the stock. Acorda Therapeutics presently has a consensus rating of “Hold” and a consensus target price of $21.47.

A number of institutional investors have recently modified their holdings of the business. GSA Capital Partners LLP purchased a new position in Acorda Therapeutics in the third quarter worth about $541,000. Convergence Investment Partners LLC purchased a new position in Acorda Therapeutics in the third quarter worth about $1,294,000. OxFORD Asset Management LLP purchased a new position in Acorda Therapeutics in the third quarter worth about $2,025,000. KBC Group NV raised its holdings in Acorda Therapeutics by 194.3% in the third quarter. KBC Group NV now owns 64,007 shares of the biopharmaceutical company’s stock worth $1,514,000 after buying an additional 42,256 shares during the last quarter. Finally, Dimensional Fund Advisors LP raised its holdings in shares of Acorda Therapeutics by 11.9% during the third quarter. Dimensional Fund Advisors LP now owns 2,655,959 shares of the biopharmaceutical company’s stock valued at $62,813,000 after purchasing an additional 283,091 shares during the last quarter.

Shares of Acorda Therapeutics (NASDAQ:ACOR) opened at $20.80 on Tuesday. The company has a current ratio of 2.77, a quick ratio of 2.40 and a debt-to-equity ratio of 0.49. Acorda Therapeutics has a 52-week low of $13.60 and a 52-week high of $33.00.

TRADEMARK VIOLATION WARNING: This article was originally published by American Banking News and is the property of of American Banking News. If you are viewing this article on another publication, it was illegally copied and reposted in violation of United States and international copyright & trademark laws. The original version of this article can be read at https://www.americanbankingnews.com/2017/12/05/177-37-million-in-sales-expected-for-acorda-therapeutics-inc-acor-this-quarter.html.

Acorda Therapeutics Company Profile

Acorda Therapeutics, Inc is a biopharmaceutical company. The Company focuses on developing therapies that restore function and improve the lives of people with neurological disorders. As of December 31, 2016, the Company marketed three United States Food and Drug Administration (FDA)-approved therapies, including Ampyra (dalfampridine) Extended Release Tablets, 10 milligram (mg), a treatment to improve walking in patients with multiple sclerosis (MS).

Get a free copy of the Zacks research report on Acorda Therapeutics (ACOR)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Acorda Therapeutics (NASDAQ:ACOR)

Receive News & Ratings for Acorda Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Acorda Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.